Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Harvard College

Sysmex Corporation

Yoshihiko Norimine

Koki Kawano

Koichi Ito

Satoshi Nagato

Fumihiro Ozaki

Kiyoaki Kobayashi

Nobuaki Sato

Kohshi Ueno

Yuichi Suzuki

Kohei Sawada

Noboru Yamamoto

Mutsuko Ono

Takashi Yoshinaga

Shinji Hatakeyama

Tatsuhiro Onogi

Hiroyuki Suzuki

Hiroe Minami

Hiroyuki Amino

Koji Hagiwara

Teiji Kimura

Yoichi Iimura

Yu Yoshida

Kunitoshi Takeda

Masataka Ueno

Yoshiaki Ohashi

Takahisa Hanada

Yuki Ishihara

Tamaki Hoshikawa

Yoshihisa Kobayashi

Nobuhiro Sato

Terence Smith

Leanne Rivers

Anthony John Groom

Makoto Ogo

Gregory Lawrence Verdine

Makoto Komatsu

Toshihiko Kaneko

Motohiro Soejima

Shigeki Iwanaga

Masaya Okada

Eriko Doi

Shinsuke Hirota

Takafumi Motoki

Tasuku Ishida

Yuji Kazuta

Daiju Hasegawa

Nobuyuki Kurusu

Yoshio Urawa

Masatoshi Suganuma

Hiroyuki Naka

Tetsuyuki Teramoto

Tetsuhiro Niidome

Kazuto Yamashita

Shingo Fujiyama

Takaaki Harada

Hikaru Yoshimura

Lourdes Gude-Rodriguez

Yoichi Nishikawa

Daiki Hara

Disclosed is: a fluorescent dye comprising a compound, a tautomer of the compound, or a salt of the compound or the tautomer; a labeled composite substance comprising the fluorescent dye and a composite substance which are bonded to each other; a composition containing the fluorescent dye or the labeled composite substance; and a method for acquiring information about a substance of interest by a super-resolution microscopy.

Fluorescent dye and use thereof

The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof: 

Pentacyclic heterocycles

The present invention provides compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof: 

Pentacyclic compound

Therapeutic conjugates containing a statin or a modified statin (collectively 'statin') linked to a therapeutic agent (also referred to as a drug herein) are targeted to the liver by the statin or modified statin and thereby deliver the therapeutic agent to liver cells.

Liver targeted conjugates

A compound represented by formula (I), or a pharmaceutically acceptable salt thereof: wherein Rrepresents a group represented by the formula: a group represented by the formula: or a group represented by the formula: and Rrepresents a 3-methyltetrahydro-2H-pyran-4-yl group or 4-methoxycyclohexyl group.

Pyridinylpyrazoloquinoline compounds

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein Ris a hydrogen atom; Ris an aromatic ring group, etc.; Ris a hydrogen atom, etc; Ris a hydrogen atom; Ris an oxepanyl group, etc.; Ris a hydrogen atom.

Pyrazoloquinoline derivatives

Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R, Rand Rrepresent hydrogen, etc., Xrepresents Calkylene, etc., Xrepresents Calkylene, etc., Arepresents a 5- to 6-membered heterocyclic group, etc., and Arepresents Caryl, etc.

Bicycloamine derivatives

The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof.  In the formula, Q indicates NH, O or S; and R, R, R, Rand Rare the same as or different from each other and each indicates hydrogen atom, a halogen atom, a Calkyl group or a group represented by the formula &#x2014;X-A (wherein X indicates a single bond, an optionally substituted Calkylene group etc.; and A indicates an optionally substituted Caromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).

1,2-dihydropyridine compounds, manufacturing method thereof and use thereof

Compounds represented by the following general formula: [wherein X, X, Xand Xeach independently represent a single bond, Calkylene, etc.; Arepresents optionally substituted phenyl, etc.; Arepresents an optionally substituted 5- to 7-membered heterocyclic group containing &#x2014;C(=Q)- (wherein Qrepresents oxygen, sulfur or &#x2550;N&#x2014;R(wherein Rrepresents hydrogen or Calkyl)) and nitrogen, etc.; and Zrepresents piperidin-diyl, etc.],salts thereof and hydrates of the foregoing.

Nitrogen containing heterocyclic compounds and medicines containing the same

The present invention provides compounds represented by the following formula:wherein X, X, Xand Xeach independently represents a single bond, Calkylene, etc.; Arepresents optionally substituted phenyl, etc.; Arepresents an optionally substituted 5- to 7-membered heterocyclic group containing &#x2014;C(&#x2550;Q)&#x2014;, Qwherein represents oxygen, sulfur or &#x2550;N&#x2014;R, wherein Rrepresents hydrogen or Calkyl etc.; and Zrepresents piperidin-diyl, ect, salts thereof and hydrates of the foregoing.

The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R, R, R, Rand Rare the same as or different from each other and each indicates hydrogen atom, a halogen atom, a Calkyl group or a group represented by the formula &#x2014;X-A (wherein X indicates a single bond, an optionally substituted Calkylene group etc.; and A indicates an optionally substituted Caromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).

1,2-dihydropyridine compounds, process for preparation of the same and use thereof

N,N-substituted cyclic amine derivatives

Nitrile compound

Growing community of inventors

Tsukuba, Japan

Yoshihiko Norimine